Search research articles
Contact Us
Filters
Showing results (501-510 of 519) with videos related to
Page
of 52
Sort By:
The New England Journal of Medicine
|
May 20, 2014
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis
Talmadge E King, Williamson Z Bradford, Socorro Castro-Bernardini, et al.
The European Respiratory Journal
|
December 10, 2015
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials
Paul W Noble, Carlo Albera, Williamson Z Bradford, et al.
Respiratory Medicine
|
May 16, 2017
The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease
Julie Morisset, Eric Vittinghoff, Bo Young Lee, et al.
BMJ Open Respiratory Research
|
February 3, 2016
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials
Lisa Lancaster, Carlo Albera, Williamson Z Bradford, et al.
International Immunopharmacology
|
December 12, 2023
Expansion of distinct peripheral blood myeloid cell subpopulations in patients with rheumatoid arthritis-associated interstitial lung disease
Jill A Poole, Kathryn E Cole, Geoffrey M Thiele, et al.
Genomics
|
January 1, 1997
A yeast artificial chromosome (YAC) contig encompassing the critical region of the X-linked lymphoproliferative disease (XLP) locus
A Lanyi, B Li, S Li, et al.
Science (New York, N.Y.)
|
June 20, 1998
Mutation of a gene encoding a protein with extracellular matrix motifs in Usher syndrome type IIa
J D Eudy, M D Weston, S Yao, et al.
Transplantation
|
September 23, 2003
Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation
Steven Z Pavletic, R Gregory Bociek, James M Foran, et al.
Thorax
|
March 13, 2016
Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis
Steven D Nathan, Carlo Albera, Williamson Z Bradford, et al.
The European Respiratory Journal
|
July 27, 2014
Smoking-related idiopathic interstitial pneumonia
Kevin R Flaherty, Charlene Fell, Marie-Christine Aubry, et al.
Page
of 52
Search research articles
Search
Showing results (501-510 of 519) with videos related to
Sort By:
Page
of 52
The New England Journal of Medicine
|
May 20, 2014
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis
Talmadge E King, Williamson Z Bradford, Socorro Castro-Bernardini, et al.
The European Respiratory Journal
|
December 10, 2015
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials
Paul W Noble, Carlo Albera, Williamson Z Bradford, et al.
Respiratory Medicine
|
May 16, 2017
The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease
Julie Morisset, Eric Vittinghoff, Bo Young Lee, et al.
BMJ Open Respiratory Research
|
February 3, 2016
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials
Lisa Lancaster, Carlo Albera, Williamson Z Bradford, et al.
International Immunopharmacology
|
December 12, 2023
Expansion of distinct peripheral blood myeloid cell subpopulations in patients with rheumatoid arthritis-associated interstitial lung disease
Jill A Poole, Kathryn E Cole, Geoffrey M Thiele, et al.
Genomics
|
January 1, 1997
A yeast artificial chromosome (YAC) contig encompassing the critical region of the X-linked lymphoproliferative disease (XLP) locus
A Lanyi, B Li, S Li, et al.
Science (New York, N.Y.)
|
June 20, 1998
Mutation of a gene encoding a protein with extracellular matrix motifs in Usher syndrome type IIa
J D Eudy, M D Weston, S Yao, et al.
Transplantation
|
September 23, 2003
Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation
Steven Z Pavletic, R Gregory Bociek, James M Foran, et al.
Thorax
|
March 13, 2016
Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis
Steven D Nathan, Carlo Albera, Williamson Z Bradford, et al.
The European Respiratory Journal
|
July 27, 2014
Smoking-related idiopathic interstitial pneumonia
Kevin R Flaherty, Charlene Fell, Marie-Christine Aubry, et al.
Page
of 52